- Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
- Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
- Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
- Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
- Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
- Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
- Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
More ▼
Key statistics
On Friday, Biora Therapeutics Inc (BIOR:NMQ) closed at 0.731, 24.96% above the 52 week low of 0.585 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.70 |
---|---|
High | 0.748 |
Low | 0.67 |
Bid | 0.712 |
Offer | 0.749 |
Previous close | 0.7128 |
Average volume | 238.34k |
---|---|
Shares outstanding | 35.88m |
Free float | 35.59m |
P/E (TTM) | -- |
Market cap | 26.23m USD |
EPS (TTM) | -8.57 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼